ArticleHepatobiliary surgery and nutrition2019
Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients.
Article in Hepatobiliary surgery and nutrition, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 50 citations in OpenAlex.
- Revealing the Potential Associations of Mutation-Related Genes with Lymph Node Metastasis in Gallbladder Cancer Through Transcriptome and Exome Sequencing.Biomedicines · 2026Article
- Molecular insights into HER2/ERBB2 amplification and carcinogenesis in gallbladder cancer associated with pancreaticobiliary maljunction.Journal of gastroenterology · 2026Article
- Precision medicine for advanced biliary tract cancer in China: current status and future perspectives.Frontiers of medicine · 2025Review
- Development and challenges in the treatment of advanced gallbladder cancer (Review).Oncology letters · 2025Review
- HIC1 suppresses Tumor Progression and Enhances CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Epidemiology and genomic features of biliary tract cancer and its unique features in Korea.Journal of liver cancer · 2025Article
- Full-length transcriptome atlas of gallbladder cancer reveals trastuzumab resistance conferred by ERBB2 alternative splicing.Signal transduction and targeted therapy · 2025Article
- What eliminates the chance for cure: a multi-center evaluation on 10-year follow-up of gallbladder cancer after surgical resection.Annals of medicine · 2024Article
- Review
- Isoalantolactone suppresses gallbladder cancer progression via inhibiting the ERK signalling pathway.Pharmaceutical biology · 2023Article
- Article
- Globo H ceramide is an independent prognostic marker for gallbladder cancer.American journal of cancer research · 2023Article
- Establishment of two oxaliplatin-resistant gallbladder cancer cell lines and comprehensive analysis of dysregulated genes.Open medicine (Warsaw, Poland) · 2023Article
- Gallbladder cancer: current and future treatment options.Frontiers in pharmacology · 2023Review
- MAP kinase and mammalian target of rapamycin are main pathways of gallbladder carcinogenesis: results from bioinformatic analysis of next generation sequencing data from a hospital-based cohort (NCT05404347).Molecular biology reports · 2022Article
- Gallbladder cancer.Nature reviews. Disease primers · 2022Review
- Quantitative detections of TP53 gene mutations improve the diagnosis and prognostic prediction of biliary tract cancers using droplet digital PCR.Journal of clinical laboratory analysis · 2022Article
- Review
- Current challenges to underpinning the genetic basis for cholangiocarcinoma.Expert review of gastroenterology & hepatology · 2021Review
- T2 gallbladder cancer shows substantial survival variation between continents and this is not due to histopathologic criteria or pathologic sampling differences.Virchows Archiv : an international journal of pathology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGallbladder cancer (GBC) is often diagnosed at an advanced stage with limited therapeutic options and poor prognosis. The five-year survival rate of this cancer when diagnosed at an advanced stage is below 5%, and the median survival time is less than a year with standard gemcitabine-based chemotherapy. Survival benefit with second-line treatment is unknown. Thus, there is an urgent need for novel treatment strategies and targeted therapy based on next generation sequencing (NGS) may be of value.
methodsComprehensive genomic profiling (CGP) was performed with NGS panel on paraffin-embedded tumors from a cohort of 108 Chinese and 107 US GBC patients. Clinical data were collected using an IRB approved protocol from a single-center in US and from China.
resultsIn Chinese and US GBC cohorts, an average of 6.4
conclusionsIn our study, over 83% Chinese and 68% US GBC patients had actionable alterations that could potentially guide and influence personalized treatment options. The identification of high TMB,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.